XML 28 R17.htm IDEA: XBRL DOCUMENT
v3.19.2

GOODWILL AND OTHER INTANGIBLE ASSETS (Notes) | 9 Months Ended
--- | ---
Jul. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND OTHER INTANGIBLE ASSETS | GOODWILL AND OTHER INTANGIBLE ASSETS The following table presents goodwill balances and the movements for each of our reportable segments during the nine months ended July 31, 2019:
| Life Sciences and Applied Markets |  | Diagnostics and Genomics |  | Agilent CrossLab |  | Total
| (in millions)
Goodwill as of October 31, 2018 | $ | 803 |  |  | $ | 1,607 |  |  | $ | 563 |  |  | $ | 2,973 |
Foreign currency translation impact | (3 | ) |  | (3 | ) |  | (2 | ) |  | (8 | )
Goodwill arising from acquisitions and adjustments | 153 |  |  | (11 | ) |  | — |  |  | 142 |
Goodwill as of July 31, 2019 | $ | 953 |  |  | $ | 1,593 |  |  | $ | 561 |  |  | $ | 3,107 |
The components of other intangible assets as of July 31, 2019 and October 31, 2018 are shown in the table below:
| Purchased Other Intangible Assets
| Gross Carrying Amount |  | Accumulated Amortization and Impairments |  | Net Book Value
| (in millions)
As of October 31, 2018 |  |  |  |  |  |  |  |
Purchased technology | $ | 947 |  |  | $ | 683 |  |  | $ | 264 |
Trademark/Tradename | 151 |  |  | 88 |  |  | 63 |
Customer relationships | 107 |  |  | 63 |  |  | 44 |
Third-party technology and licenses | 28 |  |  | 19 |  |  | 9 |
Total amortizable intangible assets | 1,233 |  |  | 853 |  |  | 380 |
In-Process R&D | 111 |  |  | — |  |  | 111 |
Total | $ | 1,344 |  |  | $ | 853 |  |  | $ | 491 |
As of July 31, 2019 |  |  |  |  |  |  |  |
Purchased technology | $ | 1,025 |  |  | $ | 739 |  |  | $ | 286 |
Trademark/Tradename | 153 |  |  | 98 |  |  | 55 |
Customer relationships | 127 |  |  | 75 |  |  | 52 |
Third-party technology and licenses | 28 |  |  | 21 |  |  | 7 |
Total amortizable intangible assets | 1,333 |  |  | 933 |  |  | 400 |
In-Process R&D | 111 |  |  | — |  |  | 111 |
Total | $ | 1,444 |  |  | $ | 933 |  |  | $ | 511 |
On November 14, 2018, we acquired 100 percent of the stock of ACEA Biosciences (“ACEA”), a developer of cell analysis tools, for approximately $250 million in cash. The financial results of ACEA have been included within our financial results from the date of the close. The purchase accounting for this acquisition is substantially complete and will be finalized during 2019, as we assess the tax impact and finalize the intangibles valuation of the acquisition. During the nine months ended July 31, 2019, we recorded additions to goodwill of $153 million related primarily to the ACEA acquisition within the life sciences and applied markets business. In the second quarter of fiscal year 2019, we recorded a measurement period adjustment to goodwill of $11 million for deferred tax assets related to pre-acquisition net operating losses of Advanced Analytical Technologies, Inc. During the nine months ended July 31, 2019, we recorded additions to other intangible assets of $103 million primarily related to the ACEA acquisition. During the nine months ended July 31, 2019, other intangible assets, net decreased $1 million due to foreign exchange translation impact. In general, for United States federal tax purposes, goodwill from asset purchases is deductible, however any goodwill created as part of a stock acquisition is not deductible. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. There were no indicators of impairments of indefinite-lived intangible assets or goodwill during the three and nine months ended July 31, 2019 and 2018, respectively. Amortization expense of intangible assets was $27 million and $82 million for the three and nine months ended July 31, 2019, respectively. Amortization expense of intangible assets was $28 million and $80 million for the three and nine months ended and July 31, 2018, respectively. Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2019 and for each of the five succeeding fiscal years and thereafter is estimated below:
Estimated future amortization expense: |
(in millions) |
Remainder of 2019 | $ | 26 |
2020 | $ | 94 |
2021 | $ | 81 |
2022 | $ | 65 |
2023 | $ | 55 |
2024 | $ | 46 |
Thereafter | $ | 33 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration